COMP <GO>
ADMA vs BEAM // EV/EBITDA & P/E VALUATION
ADMA Biologics Inc (NASDAQ) VS. Beam Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ADMA 7
— BEAM 2
■ METRIC PARITY
LAST: $11.75 (+4.17%) • MKT CAP: $2.63B
valuation
12.4x
LAST: $28.84 (+0.21%) • MKT CAP: $2.98B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADMA VS. BEAM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADMA | BEAM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 32.90% | -32.10% | +65.00 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.06% | -12.09% | +13.15 | ADMA | /fcf-yield <GO> |
| Operating Margin | 37.50% | -60.00% | +97.50 | ADMA | /operating-margins <GO> |
| Net Profit Margin | 28.80% | -57.20% | +86.00 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 19.60% | 120.00% | -100.40 | BEAM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.98 | 6.00 | +6.98 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | ADMA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.1 | 57.7 | +6.39 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.63B | $2.98B | -$347.0M | BEAM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADMA REV | BEAM REV | ADMA GROSS % | BEAM GROSS % | ADMA FCF | BEAM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $510.2M | $139.7M | 57.4% | — | $27.8M | -$360.0M |
| FY 2024 | $426.5M | $63.5M | 51.5% | — | $110.4M | -$356.2M |
| FY 2023 | $258.2M | $377.7M | — | — | $8.8M | -$149.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADMA // BETA —
BEAM // BETA —